ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
207 |
82K |
6 |
14:03 |
14:03 |
ASX - By Stock
|
207
|
82K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
16 |
13:25 |
13:25 |
ASX - By Stock
|
533
|
194K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
207 |
82K |
16 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
207
|
82K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
207 |
82K |
17 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
207
|
82K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
207 |
82K |
60 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
207
|
82K
|
60
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
13 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
533
|
194K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
5 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
533
|
194K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
50 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
533
|
194K
|
50
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Phaedrus
|
38 |
16K |
25 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
16K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Phaedrus
|
38 |
16K |
29 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
16K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
17K |
6.6M |
20 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
169K |
8 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
549
|
169K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
5 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
133
|
44K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
551 |
194K |
3 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
551
|
194K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
20 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
44K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
55 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
44K
|
55
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
15 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
44K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
44K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
169K |
20 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
549
|
169K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
45 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
44K
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
44K |
35 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
44K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
527 |
203K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
527
|
203K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
21 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
5 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
5 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
533
|
194K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
14 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
533
|
194K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
15 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
533
|
194K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
16 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
533
|
194K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
533 |
194K |
36 |
06/04/24 |
06/04/24 |
ASX - By Stock
|
533
|
194K
|
36
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
15 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
15
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
8 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
13 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
9.4K |
2.7M |
12 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Upcoming Newsflow & Re-rate Estimations
|
|
Phaedrus
|
52 |
22K |
53 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
52
|
22K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Upcoming Newsflow & Re-rate Estimations
|
|
Phaedrus
|
52 |
22K |
23 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
52
|
22K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
Phaedrus
|
116 |
41K |
21 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
116
|
41K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
Phaedrus
|
116 |
41K |
9 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
116
|
41K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
MSB shareholder class action
|
|
Phaedrus
|
116 |
41K |
6 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
116
|
41K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
17K |
6.6M |
11 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
272 |
98K |
6 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
272
|
98K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
ASX Hot too!
|
|
Phaedrus
|
60 |
22K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
60
|
22K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
272 |
98K |
7 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
272
|
98K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
88 |
37K |
17 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
88
|
37K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
88 |
37K |
42 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
88
|
37K
|
42
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
551 |
194K |
12 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
551
|
194K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
17K |
6.6M |
6 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
17K |
6.6M |
9 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
How to Loan out shares on ASX??
|
|
Phaedrus
|
30 |
8.6K |
18 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
30
|
8.6K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
527 |
203K |
2 |
01/04/24 |
01/04/24 |
ASX - By Stock
|
527
|
203K
|
2
|
|